𝗡𝗲𝘄 𝗼𝗻 𝘁𝗵𝗲 𝗦𝗰𝗶𝗲𝗻𝗰𝗲 𝗣𝗼𝗼𝗹, 𝗼𝘂𝗿 𝗼𝗻𝗹𝗶𝗻𝗲 𝗿𝗲𝘀𝗼𝘂𝗿𝗰𝗲 𝗵𝘂𝗯! Tuberculosis (TB) remains one of the deadliest infectious diseases worldwide — and drug resistance is on the rise. At Evotec, we’re tackling this global challenge head-on with a comprehensive, 𝗲𝗻𝗱-𝘁𝗼-𝗲𝗻𝗱 𝗧𝗕 𝗿𝗲𝘀𝗲𝗮𝗿𝗰𝗵 𝗽𝗹𝗮𝘁𝗳𝗼𝗿𝗺 𝘁𝗵𝗮𝘁 𝘀𝗽𝗮𝗻𝘀: • Target ID & validation • In vitro & in vivo efficacy models • Biomarker development • Global partnerships & access to clinical expertise 𝗢𝘂𝗿 𝗹𝗮𝘁𝗲𝘀𝘁 𝗯𝗹𝗼𝗴 𝗱𝗶𝘃𝗲𝘀 𝗶𝗻𝘁𝗼 𝗵𝗼𝘄 𝘄𝗲'𝗿𝗲 𝗮𝗰𝗰𝗲𝗹𝗲𝗿𝗮𝘁𝗶𝗻𝗴 𝗽𝗿𝗲𝗰𝗹𝗶𝗻𝗶𝗰𝗮𝗹 𝗧𝗕 𝗱𝗿𝘂𝗴 𝗱𝗶𝘀𝗰𝗼𝘃𝗲𝗿𝘆 - with the right science, the right infrastructure, and the right global collaborators. One platform. Many possibilities. A clear path from discovery to the clinic. 𝗥𝗲𝗮𝗱 𝗺𝗼𝗿𝗲- https://hubs.ly/Q03B5nsK0 #TB #Tuberculosis
Evotec Anti-Infectives
Arzneimittelherstellung
Your partner in anti-infective drug discovery and development, from target identification to IND and beyond.
Info
Evotec is a drug discovery and development partnership organisation and collaborates with numerous partners across the world to develop new anti-infectives. We efficiently move programs from target identification to investigational new drug (“IND”) status and have established a proven track record of contributing to the identification and characterisation of multiple anti-infective agents from pre-clinical candidates through to marketed drugs. Evotec has established a leading-edge platform enabling the discovery and development of new therapies and therapeutic approaches to treat and prevent serious and life-threatening infections. Our expertise encompasses antibacterials, antifungals, antivirals, and antiparastics. Integration, innovation and efficiency are the main elements characterising Evotec’s expertise and capabilities. We reach far beyond conventional antimicrobial agents into alternative modalities such as targeting virulence attributes, specific pathogen antibodies, combination therapies, antimicrobial peptides (AMPs) and phage technologies. Our team has also developed a highly successful track record in collaborative funding applications in both Europe and the US. Our anti-infective platform: • EvostrAIn™ – An extensive range of geographically diverse human pathogenic bacteria and fungi including isolates that are susceptible and resistant to current antimicrobial drugs. • In vitro and in vivo microbiology encompassing Gram positive and Gram negative pathogens (including anaerobes) in a wide range of animal models with a broad range of endpoints. • Translational in vitro and in vivo PK/PD and mathematical modelling with emphasis on in vitro Hollow Fibre Systems to mimic defined drug exposure profiles. • In vitro and in vivo virology, focusing on respiratory viruses such as RSV, HRV, influenza virus and human coronavirus (enabling COVID-19 work). • In vitro and in vivo mycology: human pathogens including Candida spp. Aspergillus spp. and parasitology
- Website
-
https://www.evotec.com/en/execute/therapeutic-areas/anti-infectives
Externer Link zu Evotec Anti-Infectives
- Branche
- Arzneimittelherstellung
- Größe
- 1.001–5.000 Beschäftigte
- Hauptsitz
- Hamburg
- Gegründet
- 1993
Updates
-
We’re proud to share that Evotec contributed to a groundbreaking study published in Nature, led by a collaborative team including Johnson & Johnson and London School of Hygiene and Tropical Medicine, U. of London. The paper presents JNJ-6640, a first-in-class small-molecule inhibitor of PurF. This novel mechanism disrupts bacterial DNA replication and shows potent activity against drug-resistant TB strains. Evotec’s intramacrophage and foamy macrophage assays played a key role in characterizing the compound’s efficacy in physiologically relevant host environments, helping to validate its potential as a therapeutic candidate. This work opens a promising new therapeutic avenue in TB drug discovery. Discover more here: https://hubs.ly/Q03vzD650 #TB #DrugDiscovery
-